missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human PDE3A (aa 575-691) Control Fragment Recombinant Protein
Click to view available options
Quantité:
100 μl
Conditionnement:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (81%), Rat (81%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-82503 (PA5-82503. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
Cyclic nucleotide phosphodiesterases (PDEs) comprise a complex group of enzymes, and at least 5 major PDE families or classes with distinctive properties have been identified. Members of the cGMP-inhibited cAMP PDE (cGI-PDE) family, such as PDE3A, are characterized by high affinity for cAMP and cGMP and competitive inhibition of their cAMP hydrolytic activity by cGMP and certain positive inotropic agents (Meacci et al., 1992 [PubMed 1315035]).
Spécification
Spécification
| Numéro d’adhésion | Q14432 |
| Concentration | ≥5.0 mg/mL |
| À utiliser avec (application) | Blocking Assay, Control |
| Formule | 1 M urea, PBS with no preservative; pH 7.4 |
| Identification génétique (Entrez) | 5139 |
| Nom | Human PDE3A (aa 575-691) Control Fragment |
| Quantité | 100 μl |
| État réglementaire | RUO |
| Alias de gène | A930022O17Rik; C87899; cAMP phosphodiesterase, myocardial cGMP-inhibited; CGI-PDE; CGI-PDE A; CGI-PDE-A; cGMP-inhibited 3',5'-cyclic phosphodiesterase A; cGMP-inhibited phosphodiesterase; cyclic GMP-inhibited phosphodiesterase A; cyclic nucleotide phosphodiesterase; HTNB; PDE3A; phosphodiesterase 3 A; phosphodiesterase 3 A, cGMP inhibited; phosphodiesterase 3 A, cGMP-inhibited; RNPDE3A |
| Nom usuel | PDE3A |
| Afficher plus |
Correction du contenu d'un produit
Veuillez fournir vos retours sur le contenu du produit en remplissant le formulaire ci-dessous.
Nom du produit
Vous avez repéré une opportunité d'amélioration ?Partager une correction de contenu